EPS for Agile Therapeutics, Inc. (AGRX) Expected At $-0.25

February 15, 2018 - By Peter Erickson

 EPS for Agile Therapeutics, Inc. (AGRX) Expected At $ 0.25
Investors sentiment increased to 1.35 in Q3 2017. Its up 0.74, from 0.61 in 2017Q2. It improved, as 9 investors sold Agile Therapeutics, Inc. shares while 8 reduced holdings. 11 funds opened positions while 12 raised stakes. 23.16 million shares or 7.44% more from 21.56 million shares in 2017Q2 were reported.
Alyeska Inv Grp Limited Partnership reported 840,169 shares stake. Aisling Cap Limited Liability holds 1.80M shares or 1.32% of its portfolio. Franklin Resources reported 0.01% of its portfolio in Agile Therapeutics, Inc. (NASDAQ:AGRX). Vanguard Gp reported 670,032 shares stake. Northern Tru Corporation holds 0% of its portfolio in Agile Therapeutics, Inc. (NASDAQ:AGRX) for 28,097 shares. Renaissance Technologies Limited Company holds 88,500 shares. The Ohio-based Meeder Asset Mgmt has invested 0% in Agile Therapeutics, Inc. (NASDAQ:AGRX). 18,266 were accumulated by Savings Bank Of Ny Mellon. Investor Ab reported 3.51 million shares or 1.01% of all its holdings. Neuberger Berman Grp Ltd holds 137,500 shares or 0% of its portfolio. Bnp Paribas Arbitrage reported 523 shares. Glenmede Tru Na owns 9,323 shares. Wells Fargo & Mn has 1,500 shares for 0% of their portfolio. Cormorant Asset reported 0.98% in Agile Therapeutics, Inc. (NASDAQ:AGRX). Millennium Mngmt Ltd Liability Com has invested 0% in Agile Therapeutics, Inc. (NASDAQ:AGRX).

Analysts expect Agile Therapeutics, Inc. (NASDAQ:AGRX) to report $-0.25 EPS on March, 14.They anticipate $0.04 EPS change or 13.79 % from last quarter’s $-0.29 EPS. After having $-0.22 EPS previously, Agile Therapeutics, Inc.’s analysts see 13.64 % EPS growth. The stock decreased 1.08% or $0.04 during the last trading session, reaching $3.66. About 68,415 shares traded. Agile Therapeutics, Inc. (NASDAQ:AGRX) has declined 48.71% since February 15, 2017 and is downtrending. It has underperformed by 65.41% the S&P500.

Agile Therapeutics, Inc. (NASDAQ:AGRX) Ratings Coverage

Among 6 analysts covering Agile Therapeutics (NASDAQ:AGRX), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Agile Therapeutics had 21 analyst reports since December 30, 2015 according to SRatingsIntel. The stock has “Buy” rating by Cantor Fitzgerald on Monday, November 6. The stock has “Buy” rating by Noble Financial on Wednesday, December 30. Noble Financial maintained the shares of AGRX in report on Thursday, November 9 with “Buy” rating. The rating was maintained by Cantor Fitzgerald with “Buy” on Tuesday, October 10. Noble Financial maintained the shares of AGRX in report on Monday, June 12 with “Buy” rating. The firm earned “Buy” rating on Friday, July 14 by RBC Capital Markets. On Friday, July 28 the stock rating was maintained by Noble Financial with “Buy”. H.C. Wainwright maintained the shares of AGRX in report on Friday, July 28 with “Buy” rating. The stock of Agile Therapeutics, Inc. (NASDAQ:AGRX) earned “Buy” rating by H.C. Wainwright on Friday, December 22. The firm earned “Buy” rating on Monday, November 20 by Cantor Fitzgerald.

Agile Therapeutics, Inc., a forward-thinking women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. The company has market cap of $125.12 million. The Company’s lead product candidate is Twirla, also known as AG200-15, a once-weekly contraceptive patch, which completed Phase III clinical trials. It currently has negative earnings. The firm is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

More important recent Agile Therapeutics, Inc. (NASDAQ:AGRX) news were published by: Seekingalpha.com which released: “Agile Therapeutics: Is This ~$3.50 ‘Busted IPO’ Worthy Of Investment …” on September 05, 2017, also Seekingalpha.com published article titled: “Agile Therapeutics: Sell-Off Post CRL Makes It Worth A Look”, Prnewswire.com published: “Agile Therapeutics Presents Additional Phase 3 SECURE Trial Results for Twirla …” on October 31, 2017. More interesting news about Agile Therapeutics, Inc. (NASDAQ:AGRX) was released by: Globenewswire.com and their article: “Agile Therapeutics to Present Additional Phase 3 Data at the 73rd Annual …” with publication date: September 07, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.